Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

Main Article Content

Caroline Robert
Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France

Jean Grob
Aix-Marseille University, Marseille, France

Daniil Stroyakovskiy
Moscow City Oncology Hospital, Moscow, Russia

Boguslawa Karaszewska
Przychodnia Lekarska KOMED, Konin, Poland

Axel Hauschild
University Hospital Schleswig-Holstein, Kiel, Germany

Evgeny Levchenko
6Petrov Research Institute of Oncology, St Petersburg, Russia

Vanna Sileni
Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy

Jacob Schachter
Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Claus Garbe
Department of Dermatology, University of T?bingen, T?bingen, Germany

Igor Bondarenko
Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine

Paul Nathan
Mount Vernon Cancer Centre, Northwood, UK

Antoni Ribas
University of California, Los Angeles, CA

Michael Davies
The University of Texas MD Anderson Cancer Center, Houston, TX

Keith Flaherty
Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA

Paul Burgess
Novartis Pharma AG, Basel, Switzerland

Monique Tan
Novartis Pharmaceuticals Corporation, East Hanover, NJ

Eduard Gasal
Novartis Pharmaceuticals Corporation, East Hanover, NJ

Dirk Schadendorf
University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany

Georgina Long
Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia

Keywords

Melanoma, BRAF, Patient Characteristics

Abstract

Abstract not available.

References

1. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2020.

2. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2020.

3. Tafinlar (dabrafenib) [summary of product characteristics]. Camberley, UK: NovartisPharmaceuticals UK Ltd; 2020. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Accessed July 31, 2020.

4. Mekinist (trametinib) [summary of product characteristics]. Camberley, UK: NovartisPharmaceuticals UK Ltd; 2020. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Accessed July 31, 2020.

5. Robert C, et al. N Engl J Med. 2019;381:626-636.

6. Nathan P, et al. J Clin Oncol. 2019;37:abstract 9507.

7. Long GV, et al. Lancet Oncol. 2016;17:1743-1754.

8. Osgood C, et al. J Clin Oncol. 2019;37:abstract 9508.

9. McCoach CE, et al. Ann Oncol. 2017;28:2707-2714.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.112

Article Details

How to Cite
[1]
Robert, C., Grob, J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., Nathan, P., Ribas, A., Davies, M., Flaherty, K., Burgess, P., Tan, M., Gasal, E., Schadendorf, D. and Long, G. 2020. Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s112. DOI:https://doi.org/10.25251/skin.4.supp.112.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Dermatopharmacology
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>